Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 8/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498337 | 1.00 | GRM2 (0.62) | GRM2GAACMA1MMP1MMP13 | |
| SCHEMBL15399271 | 0.84 | GRM2 (0.53) | GRM2GAACMA1MMP1MMP13 | |
| SCHEMBL16509683 | 0.84 | GRM2 (0.50) | GRM2GAACMA1MMP1MMP13 | |
| SCHEMBL13830557 | 0.82 | GRM2 (0.54) | GRM2L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL12164226 | 0.82 | GRM2 (0.54) | GRM2L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL31581616 | 0.82 | SIRT2 (0.52) | GRM2GAAMMP1MMP13L3MBTL1 | |
| SCHEMBL31564712 | 0.82 | SIRT2 (0.52) | GRM2GAACMA1MMP1MMP13 | |
| SCHEMBL31564563 | 0.82 | SIRT2 (0.52) | GRM2GAAMMP1MMP13L3MBTL1 | |
| SCHEMBL537338 | 0.81 | GRM2 (0.53) | GRM2GAACMA1MMP1MMP13 | |
| SCHEMBL31564723 | 0.81 | GRM2 (0.47) | GRM2GAACMA1MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | disclosed |
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | disclosed |
| US-6958402-B2 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| CN-1620291-A | 3-(imidazolyl)-2-alkoxypropanoic acids as TAFIA inhibitors | PFIZER (US) | 2005-05-25 | — | — | CN | disclosed |
| US-20040254164-A1 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER INC. (US) | 2004-12-16 | — | — | US | disclosed |
| EP-1467731-A1 | 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS | Pfizer Limited (GB) | 2004-10-20 | — | — | EP | disclosed |
| US-6713496-B2 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-20030199522-A1 | 3-(Imidazolyl)-2-alkoxypropanoic acids | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003061652-A1 | 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS | PFIZER LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003061652-A1 | 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS | PFIZER LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199522-A1 | 3-(Imidazolyl)-2-alkoxypropanoic acids | F2, FGB, F7 | GRM2 3210/4885GAA 4272/4885CMA1 1500/4885 |
| US-20240150362-A1 | Substituted Pyrrolotriazines | USP7, UBA7, USP5 | GRM2 4036/4885GAA 733/4885CMA1 1015/4885 |
| US-20040254164-A1 | 3-(imidazolyl)-2-alkoxypropanoic acids | F2, FGB, F7 | GRM2 3449/4885GAA 4279/4885CMA1 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.